This filing is a routine SPAC housekeeping item with no new information on a business combination target. Monitor for a definitive agreement announcement, which would trigger the equity grants and provide the first real catalyst for DMIIR.
Price Chart
Executive Summary
Drugs Made In America Acquisition II Corp. (DMIIR) formalized compensation for its CEO and updated the CFO's consulting agreement. CEO Roger Bendelac will receive $4,500/month (with up to $2,000 deferred) and 250,000 shares at deal close. CFO Saleem Elmasri's share grant was increased from 100,000 to 175,000 shares, also earned upon a definitive business combination. These are routine SPAC compensation formalizations with no financial results or business combination announced.
Key Facts
- CEO Roger Bendelac formalized compensation: $4,500/month ($2,500 payable, up to $2,000 deferred) plus 250,000 ordinary shares at business combination close.
- CFO Saleem Elmasri's share grant increased from 100,000 to 175,000 ordinary shares, earned upon definitive agreement and issued at close.
- Both equity grants are contingent on execution of a definitive business combination agreement.
- No business combination target, financial results, or material operating update provided.
Financial Impact
CEO monthly cash compensation of $4,500 (up to $2,000 deferred); CFO monthly cash compensation of $3,500. Combined equity grants of 425,000 shares at deal close.
Risk Factors
- SPAC may fail to consummate a business combination within its allotted timeframe.
- Deferred cash compensation indicates potential cash constraints.
- No target or timeline for a definitive agreement disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-048687 |
| Document: ea028797501ex10-1.htm | 0001213900-26-048687 |
| Document: ea028797501ex10-2.htm | 0001213900-26-048687 |
| Document: 0001213900-26-048687-index-headers.html | 0001213900-26-048687 |
| Document: 0001213900-26-048687-index.html | 0001213900-26-048687 |
| Document: 0001213900-26-048687.txt | 0001213900-26-048687 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers